An Apoptotic Body‐Mimetic Nanoagonist for Synergistic Diabetic Wound Immunotherapy
Advanced Healthcare Materials · 2026
DOI: 10.1002/adhm.71665 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, 2026. Verfasst von Zhuan Wang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Orthopaedics and Traumatology, Department of Orthopaedics, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China. Hauptthemen laut MEDLINE: Wound Healing, Diabetes Mellitus, Experimental, Nanoparticles. Die Arbeit nennt 41 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Guangdong Basic and Applied Basic Research Foundation, Basic and Applied Basic Research Foundation of Guangdong Province.
Abstract (Originalsprache)
Diabetic skin injury (DSI), which are challenging to heal, contribute to global economic losses exceeding US$ 250 billion annually. The impaired healing process is primarily driven by severe local inflammation, excessive oxidative stress, and restricted angiogenesis, with dysfunctional macrophage polarization being a central pathological factor. Inspired from mechanisms of apoptotic cell clearance and maintenance of tissue homeostasis in the body, herein we developed a sprayable apoptotic body‐mimic nanotherapeutic with macrophage‐targeting anti‐inflammatory and antioxidant properties, which consisted of the ‘eat me’ signal, phosphatidylserine‐exposing nanoliposome containing epigallocatechin gallate‐magnesium ion nanocomplexes (EGCG‐Mg@PSLs). Both in vitro and in vivo experiments demonstrated that macrophage‐targeted EGCG‐Mg@PSLs effectively alleviate inflammation, promote angiogenesis and collagen fiber formation, and accelerate wound closure. Network pharmacology analysis supported the therapeutic relevance of EGCG in DSI healing. Transcriptomic sequencing also revealed that EGCG‐Mg@PSLs likely modulate macrophage behavior via the MAPK signaling pathway and metabolic reprogramming. The results indicated that apoptotic body‐mimic nanotherapeutics with PS‐exposing shell and metal–phenolic complex core represent a promising bio‐inspired therapeutic strategy for macrophage immunotherapy for chronic diabetic wounds.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Orthopaedics and Traumatology, Department of Orthopaedics, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China.
- Department of Materials Science and Engineering, College of Chemistry and Materials, Jinan University, Guangzhou, Guangdong, China.
- Guangdong Provincial Key Laboratory of Gastroenterology, Department of Gastroenterology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China.
ORCID-Profile: Yusheng Yang, Yuxuan Zhang, Rong Zeng, Lei Wang
Förderung
- National Natural Science Foundation of China
- Guangdong Basic and Applied Basic Research Foundation
- Basic and Applied Basic Research Foundation of Guangdong Province
Zitieren
APA
Wang, Z., Yang, W., Yang, Y., Deng, Z., Yang, Q., Peng, Y., Zhang, Y., Meng, Y., Zeng, R., & Wang, L. (2026). An Apoptotic Body‐Mimetic Nanoagonist for Synergistic Diabetic Wound Immunotherapy. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.71665
Vancouver
Wang Z, Yang W, Yang Y, Deng Z, Yang Q, Peng Y, et al. An Apoptotic Body‐Mimetic Nanoagonist for Synergistic Diabetic Wound Immunotherapy. Advanced Healthcare Materials. 2026. doi:10.1002/adhm.71665
BibTeX
@article{Wang2026,
author = {Wang, Zhuan and Yang, Weilin and Yang, Yusheng and Deng, Zihao and Yang, Qinmeng and Peng, Yuanshu and Zhang, Yuxuan and Meng, Yan and Zeng, Rong and Wang, Lei},
title = {An Apoptotic Body‐Mimetic Nanoagonist for Synergistic Diabetic Wound Immunotherapy},
journal = {Advanced Healthcare Materials},
year = {2026},
doi = {10.1002/adhm.71665}
}
EUVIMED